Current clinical decisions for advanced NSCLC in first-line treatment are based on the presence of genetic aberrations, such as sensitizing epidermal growth factor receptor (EGFR) mutations, and translocations of anaplastic lymphoma kinase (ALK). This evidence concerns the gene ALK and non-small cell lung carcinoma.